会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • Method of using adenoviral vectors with increased persistence in vivo
    • 使用体内持续性增加的腺病毒载体的方法
    • US20060140909A1
    • 2006-06-29
    • US11208405
    • 2005-08-19
    • Thomas WickhamMasaki AkiyamaJason Gall
    • Thomas WickhamMasaki AkiyamaJason Gall
    • A61K48/00C12N15/861
    • C12N15/86A61K48/00C12N2710/10322C12N2710/10343C12N2710/10345C12N2810/405C12N2810/50
    • The invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises slowly releasing into the bloodstream a dose of replication-deficient or conditionally-replicating adenoviral vector having reduced ability to transduce mesothelial cells and hepatocytes. The normalized average bloodstream concentration of the adenovirus over 24 hours post-administration is at least about 1%. Alternatively, the normalized average bloodstream concentration over 24 hours post-administration is at least about 5-fold greater than the normalized average bloodstream concentration for an equivalent dose of a wild-type adenoviral vector. A method of destroying tumor cells in a mammal also is provided, as is a replication-deficient adenoviral vector comprising a serotype 5 or serotype 35 adenoviral genome with a serotype 41 fiber protein, wherein the replication-deficient adenoviral vector exhibits reduced native binding to integrins.
    • 本发明提供了在哺乳动物中表达外源核酸的方法。 该方法包括缓慢释放一定剂量的复制缺陷型或条件复制型腺病毒载体,其具有降低转导间皮细胞和肝细胞的能力。 给药后24小时内腺病毒的归一化平均血流浓度为至少约1%。 或者,给药后24小时内的标准化平均血流浓度比相当剂量的野生型腺病毒载体的归一化平均血流浓度高至少约5倍。 还提供了破坏哺乳动物肿瘤细胞的方法,以及包含血清型5或具有血清型41纤维蛋白的血清型35腺病毒基因组的复制缺陷型腺病毒载体,其中复制缺陷型腺病毒载体表现出降低的天然与整联蛋白结合 。
    • 8. 发明申请
    • Adenoviral vector with replication-dependent transgene expression
    • 具有复制依赖性转基因表达的腺病毒载体
    • US20050063953A1
    • 2005-03-24
    • US10911957
    • 2004-08-05
    • Erik Falck-PedersenJason Gall
    • Erik Falck-PedersenJason Gall
    • A61K48/00C12N15/861
    • C12N15/86A61K48/00C12N2710/10343C12N2840/44
    • The invention provides an adenoviral vector comprising (a) at least a portion of an adenoviral genome comprising a major late transcription unit containing a terminal exon, wherein the terminal exon comprises a 5′ splice acceptor DNA sequence element and a 3′ polyadenylation signal sequence, and (b) a non-native nucleic acid sequence encoding a protein that does not contribute to the adenoviral vector entry into a host cell, wherein the non-native nucleic acid sequence is positioned within the terminal exon, such that the non-native nucleic acid sequence is selectively expressed in cells within which the adenoviral vector can replicate. The invention further provides an adenoviral vector composition and a method for treating or preventing a pathologic state in a mammal, comprising administering to the mammal the adenoviral vector composition of the invention in an amount sufficient to treat or prevent the pathologic state in the mammal.
    • 本发明提供了一种腺病毒载体,其包含(a)至少一部分腺病毒基因组,其包含含有末端外显子的主要晚期转录单位,其中所述末端外显子包含5'剪接受体DNA序列元件和3'多腺苷酸化信号序列, 和(b)编码不对腺病毒载体进入宿主细胞有贡献的蛋白质的非天然核酸序列,其中非天然核酸序列位于末端外显子内,使得非天然核酸 酸序列在腺病毒载体可以复制的细胞中选择性表达。 本发明进一步提供了一种用于治疗或预防哺乳动物病理状态的腺病毒载体组合物和方法,其包括以足以治疗或预防哺乳动物病理状态的量向哺乳动物施用本发明的腺病毒载体组合物。